CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06915025
Title field or adapter rule: {'original_value': 'A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:29.871269+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Source Retrieved At: 2026-10-31T22:18:15.087634+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Epithelial Ovarian Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06915025"
protocolSection.identificationModule.officialTitle: "A Randomized Phase 3 Trial Evaluating the Safety \u0026 Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant \u0026 Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy'], 'description': '100 mg/m2 IP given weekly during frontline treatment', 'name': 'IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Control Arm: SOC Chemotherapy + SOC Maintenance Therapy', 'Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy'], 'description': '175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Control Arm: SOC Chemotherapy + SOC Maintenance Therapy', 'Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy'], 'description': 'AUC 6 IV given every 21 days for 6 cycles during frontline treatment', 'name': 'Carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Control Arm: SOC Chemotherapy + SOC Maintenance Therapy', 'Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy'], 'description': 'Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.', 'name': 'Olaparib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Control Arm: SOC Chemotherapy + SOC Maintenance Therapy', 'Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy'], 'description': "Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \\& HRD/BRCAwt.", 'name': 'Niraparib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.